Skip to content

THC THERAPEUTICS, INC.: 10-Q filed 2024-01-09

What THC THERAPEUTICS, INC. reported in its quarterly report filed 2024-01-09 (fiscal Q3 2023): 31 published measures, 91 facts as tagged in accession 0001477932-24-000083.

This filing

Form
10-Q (quarterly report)
Filed
2024-01-09
Fiscal period
fiscal Q3 2023
Accession
0001477932-24-000083 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All THC THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-04-3013,346USD
At 2022-07-31206,901USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-04-303,190,238USD
At 2022-07-313,216,868USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-04-30-3,276,892USD
At 2023-01-31-3,371,247USD
At 2022-10-31-5,222,989USD
At 2022-07-31-3,109,967USD
At 2022-04-30-3,858,953USD
At 2022-01-31-3,233,675USD
At 2021-10-31-2,928,334USD
At 2021-07-31-2,477,326USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-04-3015USD
At 2022-07-3132USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-02-01 to 2023-04-3094,355USD89
2022-11-01 to 2023-01-311,685,852USD92
2022-08-01 to 2022-10-31-2,134,302USD92
2022-02-01 to 2022-04-30-632,278USD89
2021-11-01 to 2022-01-31-752,460USD92
2021-08-01 to 2021-10-31-486,437USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-08-01 to 2023-04-30-85,385USD273
2021-08-01 to 2022-04-30-395,364USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-02-01 to 2023-04-300USD89
2022-08-01 to 2023-04-300USD273
2022-02-01 to 2022-04-300USD89
2021-08-01 to 2022-04-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-08-01 to 2023-04-3085,368USD273
2021-08-01 to 2022-04-30103,051USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-08-01 to 2023-04-300USD273
2021-08-01 to 2022-04-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-04-30-38,391,004USD
At 2022-07-31-38,036,909USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-08-01 to 2023-04-3087,170USD273
2021-08-01 to 2022-04-30440,048USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-02-01 to 2023-04-30-58,020USD89
2022-08-01 to 2023-04-30-439,261USD273
2022-02-01 to 2022-04-30-123,529USD89
2021-08-01 to 2022-04-30-1,213,159USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-04-30985USD
At 2022-07-3140,713USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-02-01 to 2023-04-3019,229USD89
2022-08-01 to 2023-04-3059,412USD273
2022-02-01 to 2022-04-3041,744USD89
2021-08-01 to 2022-04-30112,460USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-04-303,190,238USD
At 2022-07-313,216,868USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-04-3012,361USD
At 2022-07-3113,403USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2022-08-01 to 2023-04-300USD273
2021-08-01 to 2022-04-3097,500USD273

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-02-01 to 2023-04-3058,020USD89
2022-08-01 to 2023-04-30439,261USD273
2022-02-01 to 2022-04-30123,529USD89
2021-08-01 to 2022-04-301,213,159USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-04-300USD
At 2022-07-3125USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-02-01 to 2023-04-300USD89
2022-08-01 to 2023-04-300USD273
2022-02-01 to 2022-04-300USD89
2021-08-01 to 2022-04-300USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-02-01 to 2023-04-300USD89
2022-08-01 to 2023-04-300USD273
2022-02-01 to 2022-04-300USD89
2021-08-01 to 2022-04-300USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-02-01 to 2023-04-303,424USD89
2022-08-01 to 2023-04-3069,243USD273
2022-02-01 to 2022-04-3033,444USD89
2021-08-01 to 2022-04-30148,605USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-04-3034,146,149shares
At 2022-07-3133,891,671shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-04-3015USD
At 2022-07-3132USD
At 2022-04-303,817USD
At 2021-07-31296,130USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-04-3041,230,912USD
At 2022-07-3141,173,946USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2023-04-3012,361USD
At 2022-07-3113,403USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-02-01 to 2023-04-3094,355USD89
2022-08-01 to 2023-04-30-354,095USD273
2022-02-01 to 2022-04-30-632,278USD89
2021-08-01 to 2022-04-30-1,871,175USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2022-08-01 to 2023-04-30-354,095USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-02-01 to 2023-04-30152,375USD89
2022-08-01 to 2023-04-3085,166USD273
2022-02-01 to 2022-04-30-508,749USD89
2021-08-01 to 2022-04-30-658,016USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2022-08-01 to 2023-04-300USD273
2021-08-01 to 2022-04-300USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-08-01 to 2023-04-30282,380USD273
2021-08-01 to 2022-04-30480,997USD273

Inspect the source

Entity
THC THERAPEUTICS, INC. / CIK 0001404935
Captured
2026-09-21T17:18:57.388Z
SEC response SHA-256
f4626d642848143dc14fec3fdbe81fdaf088917037c5da7ecb43246b70ad052b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001404935.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))